INSPIRIS China PMCF Study (INSPIRIS China)
Post-Market Clinical Follow-up Study of Edwards Lifesciences INSPIRIS RESILIA Aortic Valve in Chinese Population
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
Listed as NCT05404880, this observational or N/A phase trial focuses on Aortic Valve Replacement and remains ongoing. Sponsored by Chinese Academy of Medical Sciences, Fuwai Hospital, it has been updated 14 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting
-
Jul 2025 — Sep 2025 [monthly]
Active Not Recruiting
-
Apr 2025 — Jul 2025 [monthly]
Active Not Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
▶ Show 9 earlier versions
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Apr 2024 [monthly]
Recruiting
-
Jul 2023 — Aug 2023 [monthly]
Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Recruiting
-
May 2023 — Jun 2023 [monthly]
Recruiting
-
Apr 2023 — May 2023 [monthly]
Recruiting
-
Nov 2022 — Apr 2023 [monthly]
Recruiting
-
Sep 2022 — Nov 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Edwards (Shanghai) Lifesciences Medical Supplies Co., Ltd.
- Edwards Lifesciences
- Rundo International Pharmaceutical Research & Development Co.,Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .